Restrictions on Transferring Materials. Pfizer and Peptide recognise that the biological, synthetic chemical and biochemical materials which are part of Pfizer Technology, Peptide Technology or Joint Technology, represent valuable commercial assets. Therefore, throughout the Contract Period and for seven (7) years thereafter, subject to the license rights granted in Section 5.3, Peptide and Pfizer agree not to transfer such materials of the other party or joint materials to any third party, unless prior written consent for any such transfer is obtained from the other party.
Restrictions on Transferring Materials. Abgenix recognizes that the biological and biochemical materials which are part of Pfizer Technology or Joint Technology, represent valuable commercial assets. Therefore, throughout the Contract Period and for five (5) years thereafter, Abgenix agrees not to transfer such materials to any third party, unless prior written, consent for any such transfer is obtained from Pfizer.
Restrictions on Transferring Materials. Subject to the grant of license to Pfizer in Section 5.2, Pfizer and ArQule recognize that the synthetic chemical materials, including, but not limited to, monomers, chemical components, intermediates, and reagents which are part of ArQule Technology or Pfizer Technology, represent valuable commercial assets. Therefore, throughout the Contract Period and for [*] years thereafter, ArQule and Pfizer agree not to ------------------ *Confidential treatment has been requested for the marked portion. transfer such materials received from the other party to any third party, unless prior written consent for any such transfer is obtained from the other party. For the purposes of this Section 4.5, ArQule employees outside of the Production Facility shall be viewed as third parties with respect to Pfizer Technology (i.e. materials within Pfizer Technology shall not be transferred to ArQule outside the Production Facility).
Restrictions on Transferring Materials. Pfizer and Myco recognize that the biological, synthetic chemical and biochemical materials which are part of Pfizer Non-Program Technology, Pfizer Program Technology, Myco Program Technology, Myco Non-Program Technology or Joint Technology, (collectively, the "Materials") represent valuable commercial assets. Therefore, throughout the Contract Period and the Option Period under the License Agreement and for [****] years thereafter, Myco and Pfizer agree not to transfer such materials which are part of Joint Technology or the other party's Technology to any third party, unless prior written consent for any such transfer is obtained from the other party, except as expressly permitted in this Agreement or the License Agreement. Furthermore, throughout the Contract Period and the Option Period under the License Agreement Myco agrees not to transfer such materials which are part of the Myco Non-Program Technology or Myco Program Technology to any third party for use in the Area.
Restrictions on Transferring Materials. Pfizer and Megabios -------------------------------------- recognize that the biological synthetic chemical and biochemical materials which are part of Pfizer Technology, Megabios Technology or Joint Technology, represent valuable commercial assets. Therefore, throughout the Contract Period and for five (5) years thereafter, Megabios and Pfizer agree not to transfer such materials to any third party, unless prior written consent for any such transfer is obtained from the other party; provided, however, that, this provision to the contrary notwithstanding, Pfizer and Megabios shall each be free to transfer as it sees fit materials included in its own Technology.
Restrictions on Transferring Materials. Each Party recognizes that the biological and biochemical materials which are part of Pfizer Technology, Medarex Technology or Program Technology, represent valuable commercial assets. Therefore, throughout the Contract Period and for five (5) years thereafter, each Party agrees that it will not transfer such materials of the other Party to any third party, unless prior written consent for any such transfer is obtained from such other Party.
Restrictions on Transferring Materials. (a) Pfizer and ATRIX recognize that the biological, synthetic chemical and biochemical materials, which are part of Pfizer Technology, Pfizer Patent Rights, ATRIX Technology, Atrix Patent Rights or Program Technology, represent valuable commercial assets. Therefore, subject to the terms and conditions of the License Agreement, throughout the Contract Period and for [ ** ] years thereafter, ATRIX and Pfizer agree not to transfer the materials included in Program Technology and Inventions and, in the case of Pfizer, the materials included in ATRIX Technology and Atrix Patent Rights and, in the case of ATRIX, the materials included in Pfizer Technology and Pfizer Patent Rights to any third party unless (i) prior written, consent for any such transfer is obtained from the other Party to this Agreement, or (ii) such transfer is pursuant to a subcontractor for work related to the Research Program and such subcontractor is obligated to hold such materials in confidence.
Restrictions on Transferring Materials. Pfizer and Isis recognize that the biological, synthetic chemical and biochemical materials which are part of [***], Isis Technology, Isis Know-how, [***], Isis Licensed Technology, Program Technology, or Program Know-how represent commercial assets. Therefore, throughout the Contract Period and for [***] thereafter, Isis and Pfizer agree not to transfer materials of the other party to any third party except for agents, unless prior written consent for any such transfer is obtained from the other party. Isis and Pfizer each represent that any employees, Affiliates, agents and any consultants to whom materials of the other party are transferred are bound by agreement to use such materials only as expressly permitted by this Agreement, and by assignment obligations in favor of the transferring party as are appropriate to effect the ownership provisions of Section 5.1.
Restrictions on Transferring Materials. Tanabe and OSI recognize that the Materials which are part of OSI Technology, Tanabe Technology or Improvements represent valuable commercial assets. Therefore, throughout the Contract Period and for ** thereafter (unless the other party consents thereto, which consent shall not be unreasonably withheld or delayed), each of OSI and Tanabe agrees not to transfer to any Third Party any such Materials which constitute Technology owned solely by the other party to this Agreement; provided, however, that OSI may transfer any such Materials to Vanderbilt to the extent necessary in order for OSI to perform its obligations under this Agreement and to the extent Vanderbilt is obligated at least under the same degree of confidentiality and non-use obligation as OSI is obligated hereunder. Additionally, throughout the Contract Period and for ** thereafter, OSI and Tanabe agree not to transfer to any Third Party any Materials which are part of the Improvements (except that OSI may transfer any such Materials to Vanderbilt to ------------------- ** This portion has been redacted pursuant to a request for confidential treatment.
Restrictions on Transferring Materials. The HOECHST Group and OSI recognize that the Materials which are part of OSI Technology, OSI Option Technology, HOECHST Group Technology, HOECHST Technology, HRPI Technology, or Joint Technology represent valuable commercial assets. Therefore, throughout the Contract Period and for five (5) years thereafter, OSI and the HOECHST Group agree not to transfer to any Third Party any such Materials which constitute Technology or Option Technology owned solely by a member of the HOECHST Group or OSI, respectively. Additionally, throughout the Contract Period and for six (6) months thereafter, OSI and the HOECHST Group agree not to transfer to any Third Party any Materials which are part of Joint Technology or Option Technology owned solely by OSI or a member of the HOECHST Group, unless prior consent for any such transfer is obtained from the other parties, which consent shall not be unreasonably withheld, and unless such Third Party agrees as a condition of any such transfer not to transfer the Materials further and to use the Materials only for research purposes not directed toward the development of Products.
